# Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Study · id `cardio:ct-nct02545933` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02545933](<https://clinicaltrials.gov/study/NCT02545933>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02545933

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT02545933. Randomized; no masking; primary purpose treatment. Start 2016-02 (actual); primary completion 2019-05 (actual). Results posted on 2020-08-25.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT02545933, source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)
- Started: 2016-02 (actual) (ClinicalTrials.gov record NCT02545933, source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)
- Primary completion: 2019-05 (actual) (ClinicalTrials.gov record NCT02545933, source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)
- Completion: 2020-01 (actual) (ClinicalTrials.gov record NCT02545933, source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)
- Results first posted: 2020-08-25 (ClinicalTrials.gov record NCT02545933, source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02545933, source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02545933-2020-09-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
- Acronym: VORA-PRATIC
- Condition: Myocardial Infarction
- Intervention (Drug): Prasugrel
- Intervention (Drug): Vorapaxar
- Intervention (Drug): Aspirin
- Intervention (Drug): Ticagrelor
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: Merck Sharp & Dohme LLC
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)
- Registry lists this organization as a collaborator: Merck Sharp & Dohme LLC (`cardio:org-merck-sharp-dohme-llc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y12 Receptor Inhibitors With and Without Aspirin: Results of the VORA-PRATIC Study (`cardio:pubmed-32306797`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7e5bcd59c83883da8c2467cc76202ae4d7ab81d7256116150b75e1a03de6e481
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
